T. Ichikawa et al., Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector, CANCER RES, 61(3), 2001, pp. 864-868
rRp450 is an oncolytic herpesvirus that expresses the CYP2B1 cDNA, responsi
ble for bioconverting cyclophosphamide (CPA) into the active metabolites 4-
hydroxyCPA/aldophosphamide (AP). However, formal proof of prodrug activatio
n is lacking. We report that activation of CPA in cells infected with rRp45
0 generates a time-dependent increase of diffusible 4-hydroxyCPA/AP. For in
vivo applications, a CPA-impregnated polymer was implanted into human tumo
r xenografts inoculated with rRp450. The area under the curve for 4-hydroxy
CPA/AP was 806 mug/g of tumor tissue/h when CPA was administered via intran
eoplastic polymer and 3 mug/g of tumor tissue/h when CPA was administered i
.p. Therefore, (a) a lytic virus expressing a "suicide" gene can activate a
prodrug; and (b) within rRp450-infected tumor, more prolonged and higher c
oncentrations of activated metabolites are generated by intraneoplastic com
pared with systemic administration of prodrug.